140 related articles for article (PubMed ID: 21865705)
1. Nasal-associated lymphoid tissue immunity and vaccine development.
Kodama S; Suzuki M
Adv Otorhinolaryngol; 2011; 72():110-2. PubMed ID: 21865705
[TBL] [Abstract][Full Text] [Related]
2. A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx.
Kodama S; Hirano T; Noda K; Abe N; Suzuki M
Vaccine; 2010 Mar; 28(13):2510-6. PubMed ID: 20117272
[TBL] [Abstract][Full Text] [Related]
3. Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx.
Kodama S; Hirano T; Noda K; Umemoto S; Suzuki M
Vaccine; 2011 Feb; 29(10):1881-90. PubMed ID: 21237276
[TBL] [Abstract][Full Text] [Related]
4. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
Abe N; Kodama S; Hirano T; Eto M; Suzuki M
Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899
[TBL] [Abstract][Full Text] [Related]
5. A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa.
Kodama S; Abe N; Hirano T; Suzuki M
Acta Otolaryngol; 2011 Sep; 131(9):989-96. PubMed ID: 21534717
[TBL] [Abstract][Full Text] [Related]
6. Th17 cells contribute to nontypeable Haemophilus influenzae-specific protective immunity induced by nasal vaccination with P6 outer membrane protein and α-galactosylceramide.
Noda K; Kodama S; Umemoto S; Nomi N; Hirano T; Suzuki M
Microbiol Immunol; 2011 Aug; 55(8):574-81. PubMed ID: 21605159
[TBL] [Abstract][Full Text] [Related]
7. Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx.
Noda K; Kodama S; Umemoto S; Abe N; Hirano T; Suzuki M
Vaccine; 2010 Jul; 28(31):5068-74. PubMed ID: 20478344
[TBL] [Abstract][Full Text] [Related]
8. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
[TBL] [Abstract][Full Text] [Related]
9. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.
Mason KW; Zhu D; Scheuer CA; McMichael JC; Zlotnick GW; Green BA
Vaccine; 2004 Sep; 22(25-26):3449-56. PubMed ID: 15308371
[TBL] [Abstract][Full Text] [Related]
10. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity.
Kurono Y; Yamamoto M; Fujihashi K; Kodama S; Suzuki M; Mogi G; McGhee JR; Kiyono H
J Infect Dis; 1999 Jul; 180(1):122-32. PubMed ID: 10353870
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media.
Sabirov A; Kodama S; Hirano T; Suzuki M; Mogi G
Infect Immun; 2001 May; 69(5):2964-71. PubMed ID: 11292713
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.
Kodama S; Abe N; Hirano T; Suzuki M
Laryngoscope; 2006 Feb; 116(2):331-5. PubMed ID: 16467729
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx.
Hirano T; Hou Y; Jiao X; Gu XX
FEMS Immunol Med Microbiol; 2003 Jan; 35(1):1-10. PubMed ID: 12589951
[TBL] [Abstract][Full Text] [Related]
14. Role of an immunodominant T cell epitope of the P6 protein of nontypeable Haemophilus influenzae in murine protective immunity.
McMahon M; Murphy TF; Kyd J; Thanavala Y
Vaccine; 2005 May; 23(27):3590-6. PubMed ID: 15855018
[TBL] [Abstract][Full Text] [Related]
15. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae.
Bertot GM; Becker PD; Guzmán CA; Grinstein S
J Infect Dis; 2004 Apr; 189(7):1304-12. PubMed ID: 15031801
[TBL] [Abstract][Full Text] [Related]
16. Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae-specific mucosal IgA responses in the middle ear.
Kodama S; Hirano T; Abe N; Suzuki M
Acta Otolaryngol; 2007 Aug; 127(8):809-15. PubMed ID: 17762989
[TBL] [Abstract][Full Text] [Related]
17. Maternal intranasal immunization with outer membrane protein P6 maintains specific antibody level of derived offspring.
Yamauchi K; Hotomi M; Billal DS; Suzumoto M; Yamanaka N
Vaccine; 2006 Jun; 24(25):5294-9. PubMed ID: 16697503
[TBL] [Abstract][Full Text] [Related]
18. Intranasal immunization with outer membrane protein P6 and cholera toxin induces specific sinus mucosal immunity and enhances sinus clearance of nontypeable Haemophilus influenzae.
Sabirov A; Kodama S; Sabirova N; Mogi G; Suzuki M
Vaccine; 2004 Aug; 22(23-24):3112-21. PubMed ID: 15297063
[TBL] [Abstract][Full Text] [Related]
19. Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization.
Kodama S; Suenaga S; Hirano T; Suzuki M; Mogi G
Infect Immun; 2000 Apr; 68(4):2294-300. PubMed ID: 10722632
[TBL] [Abstract][Full Text] [Related]
20. Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin.
Hotomi M; Saito T; Yamanaka N
Vaccine; 1998 Dec; 16(20):1950-6. PubMed ID: 9796049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
